Immuron Share Price - IMRN

Best deals to access real time data!
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
CHART Trader
Monthly Subscription
for only
$30.66
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Immuron Ltd IMRN NASDAQ Depository Receipt
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 3.41 0.00 0.00 0.00 3.41 04:00:00
Bid Price Ask Price Spread Spread % News
0.01 6.00 5.99 99.83% - -
Last Trade Time Type Quantity Stock Price Currency
- 0  0.00 USD

Immuron Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio
 15.07M 4.42M  -3.01M -0.90 - 4.42M
Dividends Per Share Dividend Yield
-  - 0.00% - -

more financials information »

News Immuron

Date Time Source Heading
10/17/201906:07Edgar (US Regulatory)Report of Foreign Issuer (6-k)
10/15/201906:48Edgar (US Regulatory)Report of Foreign Issuer (6-k)
10/14/201907:30GlobeNewswire Inc.Immuron North American Q1 Sales Up 111% YoY
10/04/201906:13Edgar (US Regulatory)Report of Foreign Issuer (6-k)
10/02/201909:00GlobeNewswire Inc.New U.S. Department of Defense Research Collaboration with..
10/02/201906:13Edgar (US Regulatory)Report of Foreign Issuer (6-k)
9/04/201906:07Edgar (US Regulatory)Report of Foreign Issuer (6-k)

Latest IMRN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

IMRN Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's lead product candidate, IMM-124E, is a proprietary immunomodulator agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Your Recent History
NASDAQ
IMRN
Immuron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191023 08:52:16